clinical trial · NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaCasdatifanCabozantinibPlacebo
brief summary
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.
started
Sep 8, 2025
primary completion
Apr 1, 2028
completion
Dec 1, 2030
last updated
Oct 26, 2026
official title
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol